Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Strategies that interfere with the binding of the receptor programmed cell death protein-1 (PD-1) to programmed death ligand-1 (PD-L1) have shown marked efficacy against many advanced cancers, including those that are negative for PD-L1. Precisely why patients with PD-L1 negative tumors respond to P...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Zaslavsky, Alexander B., Adams, M. P., Cao, X., Maj, T., Choi, J. E., Stangl-Kremser, J., Patel, S., Putelo, A., Lee, S. K., Nallandhighal, S., Kasputis, A., Alva, A., Lew, M., Qin, A., Mehra, R., Morgan, T. M., Salami, S. S., Reichert, Z., Udager, A., Zou, W., Palapattu, Ganesh S.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7652857/
https://ncbi.nlm.nih.gov/pubmed/33168847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-76351-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires